Skip to main content
Clinical Trials/NCT03103282
NCT03103282
Completed
Not Applicable

A Multi-center, Single Arm Post-market Clinical Study to Confirm Safety and Performance of PuraStat® Absorbable Haemostatic Material for the Management of Bleeding In Vascular Surgery.

3-D Matrix Europe SAS1 site in 1 country65 target enrollmentJune 14, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Vascular Anastomosis Surgery
Sponsor
3-D Matrix Europe SAS
Enrollment
65
Locations
1
Primary Endpoint
Total Time-To-Haemostasis
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

The objective of this post-market clinical follow-up study is to collect medical information on patients implanted with PuraStat®, according to each participating institution's procedures and standards of care.

Detailed Description

This multicentre, single arm post-market clinical study aims to collect medical information on patients implanted with PuraStat®, Absorbable Haemostatic Material, according to each participating institution's procedures and standards of care for confirming the safety and the performance of PuraStat®, for the management of bleeding in vascular surgery (Carotid Endarterectomy either by direct closure (without the use of patch), or by patch reconstruction or eversion technique).

Registry
clinicaltrials.gov
Start Date
June 14, 2017
End Date
August 30, 2019
Last Updated
5 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
3-D Matrix Europe SAS
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Total Time-To-Haemostasis

Time Frame: Intraoperatively

Total Time-To-Haemostasis (TTH) will be intraoperatively measured (secondes) from the first application of PuraStat® to a bleeding site after clamp release, until all bleeding at that site has ceased. In case of rebleeding of the treated sites and additional application of PuraStat®, the TTH will be calculated by the addition of TTH1+ TTH(n+1), where TTH1+ TTH(n+1) are the time to haemostasis after each application of PuraStat®.

Secondary Outcomes

  • Quantity of Blood Product(s) and or Substitute(s)(Intraoperatively)
  • Status Post Application(s)(Intraoperatively)
  • Assessment of Product Use(Intraoperatively)
  • Length of Hospital Stay(Discharge)
  • Blood Loss(Intraoperatively)
  • Total Drainage Volume(Post-operatively)
  • Transfusion of Blood Products(Post-operatively)

Study Sites (1)

Loading locations...

Similar Trials